Document:

EX-10.14

 Exhibit 10.14 

RESEARCH, DEVELOPMENT, ENGINEERING SERVICES 

AND LICENSE MEMORANDUM AND AGREEMENT 
 THIS
RESEARCH, DEVELOPMENT, ENGINEERING SERVICES AND LICENSE MEMORANDUM AND AGREEMENT (“Agreement”) is made by and among ProKidney, a Cayman Islands exempted limited company (“ProKidney Cayman”), a wholly-owned
subsidiary of ProKidney LP, an Irish limited partnership (“ProKidney Ireland”) (hereinafter collectively “PROKIDNEY”) and DEKA PRODUCTS LIMITED PARTNERSHIP, a New Hampshire limited partnership with its principal offices at
340 Commercial Street, Manchester, New Hampshire 03101, and its general partner, DEKA RESEARCH & DEVELOPMENT CORP., a New Hampshire corporation of the same address (hereinafter collectively “DEKA”). PROKIDNEY and DEKA shall be
referred to individually as “Party” and collectively as “Parties.” 
 WITNESSETH: 

WHEREAS, DEKA has expertise in the design, development, and testing of sophisticated mobility technology and DEKA has previously
developed and owns and, as a result of the Development Program (as defined herein), has come to develop and own and may further come to develop and own certain patent rights, copyrights, trade secrets, and/or confidential know-how relating to the ProKidney Field (as defined herein); and 
 WHEREAS, PROKIDNEY desired and
continues to desire that DEKA undertake the Development Program (as defined herein) to attempt to develop Licensed Technology (as defined herein), for use within the ProKidney Field, and PROKIDNEY is willing to remunerate DEKA for such work on the
Development Program; and 
 WHEREAS, DEKA desired and continues to desire that the Licensed Technology, if successfully developed, be
made available for use within the ProKidney Field, on the terms stated herein; and 
 WHEREAS, PROKIDNEY wished to and continues to
wish to have developed and made available such Licensed Technology, for use within the ProKidney Field, and for PROKIDNEY to obtain an exclusive, worldwide right and license to Commercialize (as defined herein) the Licensed Technology within the
ProKidney Field; 
 WHEREAS, PROKIDNEY and DEKA reached an agreement on August 30, 2021 (the “Effective Date”)
for DEKA to undertake components of the Development Program to attempt to develop Licensed Technology for use within the ProKidney Field so that PROKIDNEY could develop and make available such Licensed Technology, for use within the ProKidney Field,
and for DEKA to grant PROKIDNEY an exclusive, worldwide right and license to Commercialize the Licensed Technology within the ProKidney Field, in return for DEKA being remunerated utilizing DEKA’s Standard Reimbursement Formula (as defined
herein), but with amounts so due by PROKIDNEY to DEKA to be settled through the issuance of up to a certain number of Class B-1 Units of ProKidney Ireland (or through the issuance of an equivalent number
of Class B-1 Profits Units of ProKidney Management Equity LLC (“PMEL”), which units represent an equivalent interest) (collectively, the “Class B-1 Units”) to DEKA (with such Class B-1 Units to be valued as at the date the amounts become due by PROKIDNEY to DEKA), and, once the obligation to
procure the issuance of all such Class B-1 Units has fallen due, thereafter by cash payment by PROKIDNEY to DEKA; and 

  
 1 

 WHEREAS, the number of Class B-1 Units
available to be issued to DEKA was subject to agreement among PROKIDNEY and its two (indirect) founding investors, and this number was agreed by the founding investors to be 2,750,000 Class B-1 Units; and

 WHEREAS, PROKIDNEY and DEKA now wish to memorialize the agreements set forth above in this Agreement and set out further and more
detailed terms of such agreements in this Agreement; and 
 NOW, THEREFORE, in consideration of the promises and mutual covenants
herein contained, the Parties hereto confirm the terms agreed and further agree such more detailed terms as follows: 
 SECTION 1
DEFINITIONS 
 Where capitalized and used in this Agreement, the following terms shall have the ascribed meanings: 

1.1 The term “Affiliate” shall mean any company or other legal entity, other than PROKIDNEY or DEKA, in whatever country organized,
now or hereafter controlling, controlled by, or under common control with PROKIDNEY or DEKA, as applicable, for the period during which such control exists. The term “control” means the possession, direct or indirect, of the power (whether
or not exercised) to direct or cause the direction of the management and policies of an entity, whether through the ownership of voting securities, by contract, or otherwise, and the term “entity” includes an individual, corporation or
other entity. 
 1.2 The term “Business Day” means a day except a Saturday, a Sunday or other day on which banks in the State of
Delaware are authorized or required by a legal requirement to be closed. 
 1.3 The term “Commercial Introduction” shall mean,
with respect to Licensed Technology, the date that Licensed Technology are first made available in commercially reasonable quantities by PROKIDNEY, or PROKIDNEY uses such Licensed Technology within its operations, directly or by or through an
Affiliate, in commercially reasonable quantities. 
 1.4 The term “Confidential Information” shall mean all information,
including, without limitation, all data, samples, designs, reports, technologies, software, materials, and other information, and all copies thereof, made or disclosed for or in contemplation of the Development Program by a Party, its employees, or
its contractors (the “Disclosing Party”) to another Party, its employees or contractors (the “Receiving Party”), excluding any information that: 

a) at the time of the disclosure was known to the Receiving Party, as shown by written records, and was not previously subject to any
obligation of confidentiality; or 
 b) was generally available to the public or was otherwise part of the public domain at the time of its
disclosure without breach of a prior obligation of confidentiality; or 

  
 2 

 c) becomes generally available to the public or otherwise part of the public domain after
its disclosure other than through a breach of a confidentiality agreement (including, but not limited to, an act or omission in breach of this Agreement); or 

d) becomes known to the Receiving Party by disclosure of a third party, as shown by written records, without an obligation of confidentiality;
or 
 e) is hereafter independently developed by personnel of the Receiving Party that have not been exposed to the Confidential Information
of the Disclosing Party, PROVIDED that the burden of proving such independent development shall be on the Receiving Party; or 
 f) is, or
relates, to Intellectual Property that is owned by the Receiving Party pursuant to the terms of this Agreement. 
 1.5 The term
“PROKIDNEY Intellectual Property” shall mean, collectively, any Intellectual Property in existence prior to the commencement of the Development Program, which PROKIDNEY owns, controls, or to which PROKIDNEY is empowered to grant a license.
“PROKIDNEY Intellectual Property” shall also include any Intellectual Property developed by PROKIDNEY outside of the Development Program during the term of this Agreement. 

1.6 The term “DEKA Intellectual Property” shall mean, collectively, any Intellectual Property: (a) in existence as of the
Effective Date and incorporated by DEKA into any Licensed Technology or (b) resulting from the performance of the Development Program, which DEKA owns, controls, or is empowered to grant a license to during the Term. 

1.7 The term “Development Contractor” shall mean any person or entity performing services under the Development Program. For the
avoidance of doubt, the Advanced Regenerative Manufacturing Institute, which is also providing services to PROKIDNEY, shall not be considered as a Development Contractor to the Development Program, unless otherwise agreed by the Parties. 

1.8 The term “Development Program” shall mean all of DEKA’s efforts relating to the Licensed Technology for use in the
ProKidney Field, including, but not limited, to the development, regulatory approval, design control, continuing engineering, manufacture, and improvement of Licensed Technology, both prior to and after the Effective Date, to attempt to achieve the
Development Purpose (as defined in Section 2.1). 
 1.9 The term “Exclusive Rights and License” shall mean the rights and
licenses granted by DEKA to PROKIDNEY under Section 8.1 hereof. 
 1.10 The term “Improvements” shall mean any modification
or enhancement of any Licensed Technology that allows the Licensed Technology, or any portion thereof, to perform the same, substantially similar, or an enhanced purpose in a better, more useful, or more economical way, or which permits a better or
more economical means of manufacture or testing of the Licensed Technology, or any portion thereof. 
 1.11 The term “Intellectual
Property” shall mean, collectively, any copyright, trade secret, devices, designs, materials, know-how, technology, information, invention, patent or patent application (including all continuations, continuations-in-part, divisions, renewals, and any other patent or patent application claiming priority thereof, all patents which may be granted thereon, all reissues,
reexaminations and extensions thereof, and all foreign counterparts of any of the forgoing), methods, data, testing results, software or algorithms. 

  
 3 

 1.12 The term “Intellectual Property Losses” shall mean any and all damages,
liabilities, claims, costs, charges, judgments, settlements and expenses (including attorney’s fees) or other losses to the extent resulting from, arising out of, or incurred in connection with, or otherwise with respect to any claim by a
third-party asserting, arising from or premised upon any Intellectual Property-related right pursuant to Section 11.2. 
 1.13 The term
“ProKidney Field” shall mean the use of Licensed Technology for any purposes relating to the provision of cell therapy for treatment of renal insufficiency (including, but not limited to, collecting cells from kidneys, injecting and/or
inserting cells into kidneys, and manufacturing, monitoring, and testing of cells for injection and/or insertion of cells into kidneys). 

1.14 The term “Licensed Technology” shall mean any technology resulting from the Development Program, including but not limited to:
(a) an injection device, (b) an automated cell digester, (c) a cell stack manipulator, and (d) any other technology development project that is made part of the Development Program pursuant to the Development Plan (as may be as
may be amended from time to time by a signed writing between the Parties). 
 SECTION 2 DEVELOPMENT AND PRODUCT SUPPORT OBLIGATIONS

 2.1 Development Purpose. The purpose of the Development Program is to achieve as expeditiously as practicable, the development
and testing of Licensed Technology in accordance with the Development Plan agreed upon by the Steering Committee (and as may be amended from time to time) (the “Development Purpose”). PROKIDNEY and DEKA shall undertake the Development
Program to attempt to achieve the Development Purpose. 
 2.2 Joint Steering Committee. To manage the Development Program and attempt
to achieve the Development Purpose, PROKIDNEY and DEKA will form a joint steering committee (“Steering Committee”) as follows: 

a) Membership; Voting; Meetings. The Steering Committee shall consist of four (4) members in total, with two representatives
designated by PROKIDNEY (and reasonably acceptable to DEKA) and two representatives designated by DEKA (and reasonably acceptable to PROKIDNEY). Such Steering Committee shall act by unanimous agreement of all such members, provided, however, that
any modifications to the Development Plan shall be subject to the signed approval of the Parties. A Party may change any of its representatives at any time upon written notice to the other Party. The Steering Committee shall meet, either in person
or by telephone, approximately once each calendar quarter (unless otherwise agreed by the Steering Committee). 
 b) Purpose. The
Steering Committee shall be responsible for establishing and reviewing the progress of the Development Program toward achieving the Development Purpose. 

  
 4 

 c) Conflict Resolution. The Steering Committee shall attempt in good faith to resolve
any conflict arising within the Steering Committee, PROVIDED that, in the event that a dispute cannot be resolved promptly by the Steering Committee, the dispute may be referred to Dean Kamen (or his successor, as appointed by DEKA)
(“Mr. Kamen”), and Tim Bertram (or such person’s successor, as appointed by PROKIDNEY) (“Mr. Bertram”), for resolution. If Mr. Kamen and Mr. Bertram are not able to resolve the matter through good faith
negotiations within thirty (30) Business Days of first being presented, then either Party may pursue mediation pursuant to Section 14.4. 

2.3 Development Plan. DEKA shall lead the Development Program and, unless otherwise agreed by the Steering Committee (pursuant to the
procedures set forth in Section 2.2), DEKA shall be primarily responsible for all activities relating to the Development Program. The Development Program shall be governed by a development plan (“Development Plan”) attached hereto as
Exhibit A (as may be amended from time to time by a signed writing between the Parties), which sets forth a mutually agreed scope of work generally consistent with this Agreement, including a
non-binding cost estimate, desired deliverables, and the roles and responsibilities of DEKA and PROKIDNEY. In the event of any inconsistencies between the Development Plan and this Agreement, the terms and
conditions of this Agreement shall control. 
 2.4 DEKA Development Program Efforts. Subject to the terms of this Agreement, DEKA
shall perform the obligations assigned to it under the Development Plan and this Agreement, which shall include without limitation: 
 a)
developing prototypes of Licensed Technology for testing as described in the Development Plan; 
 b) conduct preparations and engineering
support for trials, as needed, of Licensed Technology; 
 c) cooperate with PROKIDNEY to implement an appropriate regulatory strategy for
Licensed Technology; 
 d) maintain the design history file, provide design control in compliance with DEKA’s quality system (unless
otherwise mutually agreed by the Steering Committee), and provide continuing engineering for Licensed Technology; 
 e) collaborate with
PROKIDNEY to develop an appropriate plan for the manufacture and manufacturing supply chain for the Licensed Technology; 
 f) take such
other efforts within the scope of this Agreement as set forth in the Development Plan or as otherwise agreed to by the Steering Committee. 
 DEKA shall
ensure that all Development Contractors engaged by DEKA to perform aspects of the Development Program comply with the terms and conditions of this Agreement. 

2.5 PROKIDNEY’s Development Program Efforts. Subject to the terms of this Agreement, PROKIDNEY shall perform the efforts assigned
to it under the Development Plan (or as otherwise agreed by the Steering Committee) to achieve the Development Purpose. 

  
 5 

 2.6 No Transfer of Development Program Materials. As part of the Development Program,
prototypes, tooling, fixtures, test equipment, and other materials may be utilized (“Development Program Materials”). Subject to the terms of this Agreement, DEKA shall own all Development Program Materials developed by DEKA or its
Development Contractors in conjunction with the Development Program. All such Development Program Materials provided by DEKA to PROKIDNEY for analysis, testing, and/or other activities related to the Development Program shall remain the property of
DEKA. For the avoidance of doubt, to the extent that any DEKA Intellectual Property is incorporated into any such Development Program Materials (or necessary to utilize any such Development Program Materials), such DEKA Intellectual Property shall
be included in the Exclusive Rights and License. 
 2.7 Disclaimer. Anything in this Agreement to the contrary notwithstanding, DEKA
does not extend or make any guarantees, warranties or representations regarding the successful development, testing or commercial viability of any Licensed Technology. PROKIDNEY and DEKA acknowledge that each Party is actively involved in other,
unrelated development programs of equal priority, but each Party agrees to use its Commercially Reasonable Efforts to achieve the Development Purpose. PROKIDNEY and DEKA acknowledge that any cost and time estimates provided are non-binding estimates made in good faith based upon the Development Program. 
 SECTION 3 FUNDING OF
RESEARCH AND DEVELOPMENT 
 3.1 Reimbursement. PROKIDNEY shall reimburse DEKA on a cost plus system for DEKA’s efforts (and
the efforts of DEKA’s Development Contractors) under the Development Program as described below in this Section 3.1. DEKA will bill its services at all direct labor incurred plus one hundred sixty percent (160%) labor overhead, plus direct
material, plus zero percent (0%) general and administration, plus ten percent (10%) fee; that is, according to the following formula: 
 ((L
x 2.6) + M) x 1.1 = reimbursement 
 where “L” equals direct labor and “M” equals non-labor
direct project costs (such as materials, Development Contractors, consultants, and other direct costs) (“DEKA’s Standard Reimbursement Formula”), PROVIDED that: 

a) PROKIDNEY shall be obliged to settle this reimbursement, initially, through procuring that ProKidney Ireland or PMEL, as determined by
PROKIDNEY, issues up to 2,750,000 Class B-1 Units to recipients as directed by DEKA and identified to PROKIDNEY on or prior to the date of this agreement (the “DEKA Recipients”), each of whom
shall enter into the form of subscription agreement attached as Exhibit B hereto in connection with such issuance of Class B-1 Units (the “Subscription Agreement”), with such Class B-1 Units to be valued for these purposes as at the day the reimbursement falls due to be settled by PROKIDNEY as determined in accordance with the following sentence. The Parties agree that this
obligation has fully vested on PROKIDNEY by virtue of work carried out by DEKA up to December 31, 2021 as follows: the total value of the work carried out by DEKA to December 31, 2021 amounts to $4,163,992.23 and the value of 2,750,000 Class B-1 Units as of December 31, 2021 amounts to $2,502,500.00. PROKIDNEY hereby acknowledges its present and fully vested obligation to procure the issuance, by ProKidney Ireland or PMEL, as applicable,
of these 2,750,000 Class B-1 Units to the DEKA Recipients. The Class B-1 Units issued to the DEKA Recipients in accordance with this Section shall be subject
to the provisions of the Subscription Agreements and the governing documents (including applicable transfer restrictions) of ProKidney Ireland or PMEL, as applicable. The parties agree that, as of December 31, 2021, the total cash payment due by
PROKIDNEY to DEKA equals $1,661,492.23; and 

  
 6 

 b) PROKIDNEY shall thereafter settle all further amounts due under this Section 3.1
through cash payment. 
 3.2 Taxes. DEKA is responsible for the payment and remittance of all applicable federal, state or local
taxes or foreign taxes resulting from payments received from PROKIDNEY, including payments of Class B-1 Units and cash pursuant to Section 3.1 of this Agreement. DEKA acknowledges and agrees that
DEKA is obligated to report as income all payments received from PROKIDNEY pursuant to this Agreement. DEKA agrees to and acknowledges the obligation to pay all self-employment and other taxes on such income. DEKA shall pay all applicable
unemployment and disability insurance required by the applicable jurisdictions in which DEKA conducts business. DEKA agrees to indemnify, defend and hold PROKIDNEY harmless from any liability for, or assessment of, any claims or penalties or
interest with respect to such taxes, labor or employment requirements, including any liability for, or assessment of, taxes imposed on PROKIDNEY by the relevant taxing authorities with respect to any payments made to DEKA pursuant to this Agreement
or any liability related to the withholding of such taxes. 
 SECTION 4 RESEARCH REPORTS AND ACCOUNTING 

4.1 Monthly Reporting and Reimbursement. DEKA shall furnish to PROKIDNEY during the Term written monthly reports (“Monthly
Report”) within approximately fifteen (15) days following the start of each month, containing an accounting of the reimbursement due for the preceding month. PROKIDNEY shall reimburse DEKA for all undisputed amounts within thirty (30) days
of receipt of each Monthly Report. Should PROKIDNEY wish to dispute any amount set forth in a Monthly Report, PROKIDNEY shall notify DEKA in writing, within thirty (30) days of receipt of such Monthly Report, of such disputed amount and
PROKIDNEY and DEKA shall use their respective reasonable efforts to amicably resolve the dispute. In the event that PROKIDNEY and DEKA do not amicably resolve a dispute within thirty (30) days of such written notification of dispute, the
Parties shall follow the dispute resolution procedures set forth in Section 14.4 herein. 
 4.2 Audits of Books and Records. DEKA
shall keep full, true and accurate books and records which account for the services rendered by DEKA under the Development Program, which account for the payments due to DEKA under this Section 4. Such books and records shall be maintained
until the fifth (5th) anniversary of the termination of this Agreement or the completion of the final Milestone on any Project (as described in Exhibit A) unless a longer timeframe for records
maintenance is provided in an SOW or the Development Plan. PROKIDNEY, at its own expense, shall have the right during normal business hours on ten (10) days’ prior written notice to DEKA and not more than once in any calendar year to have
a nationally recognized independent public accounting firm selected by PROKIDNEY and acceptable to DEKA examine the relevant books and records of DEKA for the two (2) preceding years for the purpose of verifying the payments under this
Section 4 for those two (2) years (PROVIDED that payments for such years have not been the subject of a prior audit). Such accounting firm shall not work on a contingency fee basis, shall execute and deliver to DEKA a standard
confidentiality agreement and shall not 

  
 7 

 
disclose to PROKIDNEY any information relating to DEKA’s business, except whether DEKA’s invoices are correct or incorrect, and if incorrect, the specific details concerning any
discrepancies and the amounts of the payment due under this Section 4. If such examination reveals a discrepancy, and neither party disputes such conclusion, PROKIDNEY shall pay to DEKA any additional amount owed to DEKA, or DEKA shall refund
to PROKIDNEY any excess payments made by PROKIDNEY, as appropriate. In the event of a dispute, the provisions of Section 14.4 shall apply. 

4.3 Inspections. During the term of this Agreement and for five (5) years thereafter, PROKIDNEY’s authorized
representative(s) and governmental regulatory authorities, shall be permitted to inspect and audit Service Provider’s premises, records, processes, software, and systems used by Service Provider in connection with this Agreement, for quality
assurance purposes. Any such PROKIDNEY audit will be conducted at PROKIDNEY’s sole expense, during DEKA’s regular business hours and upon reasonable prior notice to DEKA. In the event an audit reveals DEKA’s noncompliance, DEKA shall
immediately implement appropriate corrective action at DEKA’s expense. 
 SECTION 5 COMMERCIALIZATION AND MANUFACTURE 

5.1 Support of the Development Program. DEKA and PROKIDNEY shall use Commercially Reasonable Efforts to support the Development Program
and to attempt to achieve the Development Purpose as soon as practicable. 
 5.2 Manufacturing. Upon the request of PROKIDNEY, DEKA
(or a DEKA Affiliate) shall provide support for establishing the manufacturing supply chain for, and making arrangements for the production of, Licensed Technology as part of the Development Program, by DEKA (or a DEKA Affiliate) or by one or more
third party contract manufacturers, as mutually agreed by the Parties. Any Licensed Technology manufactured by DEKA (or a DEKA Affiliate) shall be supplied pursuant to a supply agreement(s) between DEKA, PROKIDNEY, and any other entity or entities
providing contract manufacturing services, which supply agreement(s) shall be negotiated in good faith no later than six (6) months prior to the anticipated Commercial Introduction. If the Parties agree to the use of one or more contract
manufacturers for some or all of the manufacturing supply chain and/or production, such support shall include helping to identify such contract manufacturer and assisting with the transfer of the Licensed Technology, and associated know-how, necessary to implement a manufacturing supply chain and production, as appropriate. 
 SECTION
6 PROPRIETARY INFORMATION 
 6.1 Treatment of Confidential Information. All Confidential Information of a Disclosing Party
disclosed to a Receiving Party shall be treated by the Receiving Party as confidential throughout the Term and for so long thereafter as the information remains Confidential Information. The Receiving Party shall: (i) treat and safeguard such
Confidential Information in the same manner as its own proprietary information of a similar type, which in no event shall be less than reasonable care; (ii) limit access to only those employees and contractors who need to know for purposes of
this Agreement; (iii) assure that such persons and entities are under the same obligations of confidentiality as are included in this Agreement; and (iv) assure 

  
 8 

 
that such persons do not use such Confidential Information except as necessary to perform its obligations under this Agreement, and use such Confidential Information consistent with Section 7. If
this Agreement is terminated for any reason, the Receiving Party, upon request of the Disclosing Party, shall return all Confidential Information in its possession or certify that all Confidential Information in its possession has been destroyed
within thirty (30) days of such request, except that the Receiving Party shall be permitted to maintain, at its own cost and expense, one archival copy of any Confidential Information necessary to support its regulatory compliance. Such
archival copy shall be maintained subject to the confidentiality requirements of this Agreement and shall only be used for the satisfaction of the regulatory obligations of the Receiving Party. 

6.2 Disclosures Required by Law. The Receiving Party shall not be liable to the Disclosing Party for disclosure of any Confidential
Information received hereunder if such disclosure is made pursuant to a governmental or judicial mandate, PROVIDED that the Receiving Party shall have given the Disclosing Party prompt notice of such mandate prior to the submission of such
Confidential Information, and FURTHER PROVIDED that the Receiving Party shall have cooperated with any efforts by the Disclosing Party to intervene in such proceedings or otherwise prevent such disclosure. 

SECTION 7 OWNERSHIP OF LICENSED SUBJECT MATTER 

7.1 DEKA Intellectual Property. Subject to the Exclusive Rights and License, and except as expressly set forth in Sections 7.2, DEKA
shall own title to any and all Intellectual Property created, developed and/or invented as a result of, or in conjunction with, the Development Program. 

7.2 PROKIDNEY Intellectual Property. PROKIDNEY shall own title to any and all Intellectual Property created, developed and/or invented
solely by PROKIDNEY independent of any assistance from DEKA as a result of PROKIDNEY’s own development efforts separate and apart from the Development Program. 

7.3 Cooperation. To the extent the Parties are able to do so, the Parties shall provide each other with reasonable opportunity to
advise the other and shall cooperate with each other in the prosecution of all patent applications. 
 7.4 Party Employee Agreements.
Each of the Parties represent and warrant that it and its employees have entered into agreements wherein its employees agreed to assign their rights in and to all inventions, as well as all patents and patent applications directed to such
inventions, resulting from their employment with such Party to that Party. DEKA will enforce the same so that DEKA can perfect its title to the DEKA Intellectual Property and PROKIDNEY can perfect its title to the Intellectual Property PROKIDNEY is
entitled to own under this Agreement. Furthermore, each of the Parties represents and warrants that it has caused or will cause all additional employees, or personnel performing work pursuant to the Development Program, to execute similar agreements
with respect to the rights in and to all inventions, as well as all patents and patent applications directed to such inventions, resulting from their association with such Party and will enforce such agreements so that the Party can perfect its
title to the Intellectual Property it is entitled to own under this Agreement. 

  
 9 

 SECTION 8 EXCLUSIVE RIGHTS AND LICENSE 

8.1 Exclusive Rights and License. 

a) Exclusive License. DEKA hereby grants to PROKIDNEY a worldwide, exclusive, royalty-free, perpetual, irrevocable (except as set forth
in Section 12) license to practice the DEKA Intellectual Property to make, have made, use, offer for sale, sell and import the Licensed Technology and Improvements thereto, all solely within the ProKidney Field. 

b) DEKA Development License. DEKA hereby grants PROKIDNEY an exclusive, worldwide, royalty-free, perpetual (except as set forth in
Section 12) license to use the DEKA Intellectual Property solely for the purpose of developing, in collaboration with DEKA, the Licensed Technology for commercial use in the ProKidney Field. 

c) Sublicense Rights. Subject to the terms of this Agreement, PROKIDNEY shall have the right to grant a sublicense to the rights and
license granted under this Section 8.1(a) – (b) (“Exclusive Rights and License”) for use within the ProKidney Field to any ProKidney Affiliate and, subject to DEKA’s prior written approval (not to be unreasonably withheld or
delayed), to any third party. DEKA shall provide a response to PROKIDNEY’s notice of intent to sublicense to any third party within ninety (90) days, unless otherwise agreed by the Parties. Any sublicense granted by PROKIDNEY must be
consistent herewith and PROKIDNEY shall remain responsible for performance of PROKIDNEY’s obligations hereunder. Any sublicense under this Section 8.1(c) must be subject to a confidentiality agreement no less restrictive than the
confidentiality provisions contained in Section 6 herein prior to the grant of such sublicense or transmission of any Confidential Information. 

d) PROKIDNEY Improvements. ProKidney shall own all title to any and all Improvements to the Licensed Technology conceived, created,
reduced to practice, developed and/or invented solely by ProKidney independent of any assistance from DEKA as a result of PROKIDNEY’s own development efforts separate and apart from the Development Program. 

8.2. DEKA Rights to Licensed Patents. For the avoidance of doubt, DEKA reserves all rights to the DEKA Intellectual Property, except as
specifically granted in Sections 7 and 8, including, without limitation, the right to utilize (by licensing others and otherwise) the DEKA Intellectual Property outside of the ProKidney Field during the Term. 

8.3. Section 365(n) of the Bankruptcy Code. All licenses granted under this Agreement are deemed to be, for purposes of
Section 365(n) of the Bankruptcy Code, licenses of rights to “intellectual property” as defined in Section 101 of such Code. ProKidney, as licensee, may fully exercise all of its rights and elections under the Bankruptcy Code.
The parties further agree that, if a Party elects to retain its rights as a licensee under any Bankruptcy Code, such party will be entitled to complete access to any technology licensed to it hereunder and all embodiments of such technology. Such
embodiments of the technology will be delivered to the licensee party not later than: (a) the commencement of bankruptcy proceedings against the licensor, upon written request, unless the licensor elects to perform its obligations under the
Agreement, or (b) if not delivered under the foregoing clause (a), upon the rejection of this Agreement by or on behalf of the licensor, upon written request. Any agreements supplemental hereto will be deemed to be “agreements
supplementary to” this Agreement for purposes of Section 365(n) of the Bankruptcy Code. As used herein, “Bankruptcy Code” means the U.S. Bankruptcy Code and any foreign equivalent thereto in any country having jurisdiction over a
Party or its assets. 

  
 10 

 SECTION 9 RESERVED 

This Section reserved. 
 SECTION 10 PATENT
FILINGS 
 10.1 Disclosure of Patent Filings. DEKA shall promptly disclose to PROKIDNEY, and PROKIDNEY shall promptly disclose to
DEKA, all inventions arising out of the Development Program, including patents and patent applications and any other intellectual property protections. 

10.2 DEKA Patent Filing. 

a) In the United States. For inventions that DEKA owns pursuant to Section 7.1 herein, DEKA may elect to file and prosecute patent
applications directed to any such inventions and such applications shall be filed, prosecuted, and maintained in DEKA’s name at DEKA’s expense utilizing patent counsel selected by DEKA. Should DEKA elect not to file a certain patent
application despite the written request by PROKIDNEY, PROKIDNEY may elect to file, prosecute, and maintain such patent application in DEKA’s name and at PROKIDNEY’s expense utilizing patent counsel selected by PROKIDNEY and reasonably
acceptable to DEKA. 
 b) Outside the United States. PROKIDNEY shall notify DEKA when PROKIDNEY desires that DEKA file for patent
protection in respect to DEKA Intellectual Property in any country other than the United States. Such applications shall be filed, prosecuted, and maintained by DEKA in DEKA’s name utilizing patent counsel selected by DEKA and reasonably
acceptable to PROKIDNEY. PROKIDNEY shall reimburse DEKA for reasonable mutually agreed outside patent counsel and other out-of-pocket expenses incurred in connection
with preparing, filing, and maintaining such patents and patent applications on a quarterly basis, provided, however, that if DEKA has executed a license with a third party who will make use of the patent in such country outside of the PROKIDNEY
Field, PROKIDNEY shall only be required to pay its pro rata portion of such fees and expenses. DEKA and PROKIDNEY shall work cooperatively to estimate the patent expenses to be paid on a quarterly basis. 

10.3 Cooperation. With respect to all patent applications referred to above, and to the extent the Parties are able to do so, the
Parties shall provide each other with reasonable opportunity to advise the other and shall cooperate with each other at its own expense in the prosecution of all such patent applications, such cooperation not to include retention, payment of costs
or expenses, and reimbursement of counsel and similar activities unless mutually agreed by the Parties. 
 SECTION 11 INFRINGEMENT AND
INDEMNIFICATION 
 11.1 DEKA Enforcement Actions. Each Party shall promptly notify the other in writing if the Party becomes
aware of any actually or reasonably suspected infringement or misappropriation by a third party of any DEKA or PROKIDNEY Intellectual Property including, without limitation, with such written notice any evidence available to it of such infringement
or 

  
 11 

 
misappropriation by such third party. As between the Parties to this Agreement, PROKIDNEY shall have the right, but not the obligation, to bring an Enforcement Action against such third party for
infringement of any DEKA Intellectual Property solely within the ProKidney Field and join DEKA as a party plaintiff, PROVIDED that PROKIDNEY shall bear all expenses of such Enforcement Action. DEKA shall reasonably cooperate with PROKIDNEY in such
Enforcement Action, including, without limitation, by providing PROKIDNEY with reasonable access to materials and witnesses. DEKA shall have the right to consult with PROKIDNEY and to participate in and be represented by independent counsel in such
Enforcement Action. Neither Party shall settle any such litigation, if such settlement would have a material adverse effect on the DEKA Intellectual Property or the PROKIDNEY Intellectual Property, unless the other Party gives prior, written
consent, which consent shall be timely and not be unreasonably withheld. Any damages or other monies awarded or received in settlement of an Enforcement Action brought by PROKIDNEY shall be first applied to reimburse PROKIDNEY’s reasonable
unreimbursed expenses. Any remainder relating to infringement or misappropriation within the ProKidney Field shall then be paid to PROKIDNEY, except that PROKIDNEY shall reimburse DEKA for its reasonable attorneys’ fees. For infringement of any
DEKA Intellectual Property both within and outside of the ProKidney Field, DEKA and PROKIDNEY will reasonably cooperate with any relevant DEKA licensees to determine an appropriate sharing of responsibilities and expenses for any Enforcement Action.

 11.2 Third Party Infringement Claims. In the event PROKIDNEY is charged with infringement of any Intellectual
Property-related right by a third-party based on the sale, lease, use, or manufacture of Licensed Technology, each Party shall immediately notify the other Parties of such claim in writing. PROKIDNEY shall have the exclusive to right to defend
against such claim and DEKA will reasonably cooperate with PROKIDNEY, including, without limitation, by providing PROKIDNEY with reasonable access to materials and witnesses, in any such action and shall have the right to consult with PROKIDNEY and
be represented by its own counsel. PROKIDNEY shall cover all costs of defending against such claim and PROKIDNEY shall have no remedy against DEKA for any Intellectual Property Losses. 

11.3 Freedom to Operate Analyses. Upon reasonable request of PROKIDNEY, DEKA shall provide reasonable assistance by conducting with
PROKIDNEY appropriate analyses of freedom to operate with respect to Licensed Technology, including (i) sharing lists of identified patents and patent applications that may constitute prior art references to one or more aspects of the Licensed
Technology, (ii) providing input regarding the initial prioritization of such potential prior art references, (iii) contributing technical and legal input regarding such potential prior art references, and (iv) conducting regular
coordination teleconferences and/or in person meetings between DEKA’s counsel and, as needed, technical personnel, and PROKIDNEY’s counsel regarding the substance and progress of the freedom to operate analysis. DEKA and PROKIDNEY shall
execute promptly a community of interest agreement to facilitate the cooperation between DEKA and PROKIDNEY regarding intellectual property matters relating to the Licensed Technology. If it determined that a license to a third party’s
intellectual property may be required to practice the Licensed Technology, PROKIDNEY shall be solely responsible for obtaining such third party license. 

  
 12 

 SECTION 12 TERMINATION 

12.1 Term. The term of this Agreement (“Term”) shall extend from the Effective Date through the commercial life of any
Licensed Technology, unless sooner terminated by a Party pursuant to this Section 12. 
 12.2 Termination for Breach. 

a) Upon any material breach of, or default under, this Agreement by DEKA, PROKIDNEY may terminate this Agreement: upon ninety
(90) days’ written notice to DEKA. Said notice shall become automatically effective at the end of such period unless, during such period, DEKA shall cure such breach or default. 

b) In the event of non-payment, DEKA may upon sixty (60) days’ written notice to PROKIDNEY,
terminate this Agreement. Said notice shall become automatically effective at the end of such period unless, during such period, PROKIDNEY shall cure such breach or default. 

c) In the event PROKIDNEY fails to proceed for a period of one hundred- eighty (180) days to undertake its obligations under the
Development Program as reasonably necessary to achieve the Development Purpose, DEKA may send a notice of termination to PROKIDNEY, and termination shall automatically become effective thirty (30) days following PROKIDNEY’s receipt of such
notice, unless PROKIDNEY has cured such breach. 
 d) DEKA’s rights of termination under Sections 12.2 (b) and (c), above are
DEKA’s sole rights of termination under this Agreement. 
 12.3 Termination for Convenience. PROKIDNEY shall have the right to
terminate this Agreement on ninety (90) days’ advance written notice to DEKA. During such ninety (90) day period, PROKIDNEY shall cooperate in good faith with DEKA to wind down the Development Program and PROKIDNEY shall continue to
reimburse DEKA pursuant to Sections 3 and 4, but the monthly reimbursements due to DEKA during the ninety (90) day period shall not exceed the average monthly reimbursement rate for the prior three (3) months. Upon DEKA’s receipt of
such notice, the termination shall be irrevocable. 
 12.4 Return of Rights to DEKA. If this Agreement is terminated for any reason
while work is ongoing on any Project, then, with respect to such Project: a) the Exclusive Rights and License under Section 8.1 related only to any then-uncompleted Milestones shall terminate, and b) any and all rights in and to all Licensed
Technology developed under such Milestones shall be returned to DEKA. All other Exclusive Rights and License under Section 8.1 and rights in and to all Licensed Technology shall continue in perpetuity. 

  
 13 

 SECTION 13 NOTICE 

13.1 Notices. All notices given under this Agreement shall be in writing and shall be given, if to: 

If to DEKA, to: 

DEKA Research & Development Corp. 

340 Commercial Street 

Manchester, NH 030101 

Attention: President 

With a copy to: 

Maureen K. Toohey 

Toohey Law Group LLC 

340 Commercial Street 

Manchester, NH 030101 

If to PROKIDNEY, to: 

PROKIDNEY 

329 Westpoint Blvd., Suite G 

Winston Salem, NC 27103 

Attn: Deepak Jain 

With a copy to: 

PROKIDNEY 

329 Westpoint Blvd., Suite G 

Winston Salem, NC 27103 

Attn: Tim Bertram 
 Each such
notice or other communication shall for all purposes of this Agreement be treated as effective or as having been given: (a) upon delivery, if personally delivered; (b) one (1) Business Day after
pre-paid deposit for next Business Day delivery with a commercial courier service (e.g., FedEx); or (c) five (5) Business Days after deposit, postage
pre-paid, with first class airmail (which airmail must be certified or registered). 
 SECTION 14
GENERAL 
 14.1 Use of Name. Except in furtherance of the obligations owing under, and as contemplated by, this Agreement, no
Party to this Agreement shall employ or use the name of the other Party in any promotional materials, advertising, or other publicly communicated materials without the prior written permission of such other Party. 

14.2 Indemnification by PROKIDNEY. 

a) PROKIDNEY shall indemnify, defend and hold harmless DEKA, its partners, shareholders, members, directors, managers, officers, and
employees, from and against any and all demands, claims, actions, suits, proceedings, liabilities, obligations, damages, losses, costs and expenses (including without limitation reasonable attorneys’ fees and disbursements) arising out of the
following: any claim of a third party (including, without limitation, by any person or entity in connection with the use of Licensed Technology tested or Commercialized by 

  
 14 

 PROKIDNEY or an Authorized Sublicensee under this Agreement , and any other third party) alleging damages
caused by any such Licensed Technology, or any component thereof, alleging product liability, negligence, personal injury, property damage, or any other cause of action of any nature seeking to impose liability. 

b) In the event of any claim under Section 14.2(a), DEKA shall promptly notify PROKIDNEY of such claim, PROVIDED that failure to provide
such notice shall not release PROKIDNEY from any of its indemnification obligations hereunder unless PROKIDNEY is materially prejudiced by the delay in notification. PROKIDNEY will undertake the defense of any such claim by counsel of
PROKIDNEY’s choosing and shall have control of the defense of, and have the right to compromise, any such claim. DEKA will provide PROKIDNEY with all information reasonably requested by PROKIDNEY, and will cooperate with PROKIDNEY in defending
such claim. DEKA’s reasonable actual costs in connection therewith will be reimbursed by PROKIDNEY. DEKA, at its sole option, may participate in such defense through separate counsel of its own choosing and at its own cost. 

c) Failure to Assume Defense. In the event, PROKIDNEY, within a reasonable time after notice of any such claim, fails to undertake the
defense of such claim, DEKA, upon further notice to PROKIDNEY, shall have the right to undertake the defense, compromise or settlement of such claim, subject to PROKIDNEY’s right (and continuing obligation) to assume the defense of such claim,
and subject to the DEKA’s right to obtain reimbursement to which it is due from PROKIDNEY. 
 d) No Dispute Resolution
Procedures. The provisions of Section 14.4 hereof regarding dispute resolution shall not apply to disputes with third parties arising out of this Section 14.2, but shall apply in determining the respective obligations of PROKIDNEY and
DEKA to one another under this Section 14.2. 
 14.3 Indemnification by DEKA. 

a) DEKA shall indemnify, defend and hold harmless PROKIDNEY, its partners, shareholders, members, directors, managers, officers, and
employees, from and against any and all demands, claims, actions, suits, proceedings, liabilities, obligations, damages, losses, costs and expenses (including without limitation reasonable attorneys’ fees and disbursements) arising out of any
claim by a third party alleging damages caused solely by the use of any Licensed Technology by DEKA, or any licensee of DEKA, outside of the ProKidney Field. 

b) In the event of any claim under Section 14.3(a), PROKIDNEY shall promptly notify DEKA of such claim, PROVIDED that failure to provide
such notice shall not release DEKA from any of its indemnification obligations hereunder unless DEKA is materially prejudiced by the delay in notification. DEKA will undertake the defense of any such claim by counsel of DEKA’s choosing and
shall have control of the defense of, and have the right to compromise, any such claim. PROKIDNEY will provide DEKA with all information reasonably requested by DEKA, and will cooperate with DEKA in defending such claim. PROKIDNEY’s reasonable
actual costs in connection therewith will be reimbursed by DEKA. PROKIDNEY, at its sole option, may participate in such defense through separate counsel of its own choosing and at its own cost. 

  
 15 

 c) Failure to Assume Defense. In the event, DEKA, within a reasonable time after
notice of any such claim, fails to undertake the defense of such claim, PROKIDNEY, upon further notice to DEKA, shall have the right to undertake the defense, compromise or settlement of such claim, subject to DEKA’s right (and continuing
obligation) to assume the defense of such claim, and subject to the PROKIDNEY’s right to obtain reimbursement to which it is due from DEKA. 

d) No Dispute Resolution Procedures. The provisions of Section 14.4 hereof regarding dispute resolution shall not apply to
disputes with third parties arising out of this Section 14.3, but shall apply in determining the respective obligations of PROKIDNEY and DEKA to one another under this Section 14.3. 

14.4 Mediation. 
 a) The
Parties will attempt to settle any claim or controversy arising out of this Agreement through consultation and negotiation in good faith and a spirit of mutual cooperation for at least forty-five (45) days after such claim or controversy was
brought to the attention of the other Party. If such attempts fail, then the dispute will be mediated pursuant to mutually agreeable rules of mediation by a mutually acceptable mediator, having knowledge of commercial matters as contained in this
Agreement, to be chosen by the Parties within forty-five (45) days after written notice by one of the Parties demanding mediation. If the Parties are unable to agree on a mutually acceptable mediator, then the Parties agree that the mediator
shall be selected by the American Arbitration Association. Neither Party may unreasonably withhold consent to the selection of a mediator, and the Parties will share the costs of the mediation equally. By mutual agreement the Parties may replace
mediation with some other form of alternative dispute resolution, such as neutral fact finding or a mini-trial. 
 b) Any dispute which the
Parties cannot resolve through negotiation, mediation or other form of ADR within six months of the date of the initial demand may then be submitted to a court of proper jurisdiction for resolution. The use of any ADR procedures will not be
construed under the doctrines of laches, waiver or estoppel to affect adversely the rights of either party to pursue its legal remedies. Nothing in this Section will prevent either party from resorting to judicial proceedings if (i) good faith
efforts to resolve the dispute under these procedures have been unsuccessful or (ii) interim relief from a court is necessary to prevent serious and irreparable injury to a Party or to others. 

14.5 Independent Contractor. For all purposes related to this Agreement, each Party shall be deemed an independent contractor of the
other Party, and nothing in this Agreement shall be deemed to create a relationship of employment or agency, constitute DEKA and PROKIDNEY as partners or joint venturers, or authorize one Party to bind the other to any third party under contract or
otherwise, without the express written authorization of the other Party. 
 14.6 No Further Warranties. Each Party hereto
acknowledges and agrees: 
 a) that no representation or promise not expressly contained in this Agreement has been made by the other Party
hereto or by any of its agents, employees, representatives or attorneys concerning the subject matter of this Agreement; 

  
 16 

 b) that this Agreement is not being entered into on the basis of or in reliance on any
promise or representation, express or implied, covering the subject matter hereof other than those which are set forth expressly in this Agreement ; and 

c) that each Party has had the opportunity to be represented by counsel of its own choice in this matter, including without limitation during
the negotiations which preceded the execution of this Agreement. 
 14.7 DEKA Representations and Warranties. DEKA represents and
warrants that: 
 a) DEKA Products Limited Partnership is a limited partnership duly organized, validly existing, and in good standing under
the laws of New Hampshire; 
 b) DEKA Research & Development Corp. is a corporation duly organized, validly existing, and in good
standing under the laws of New Hampshire; 
 c) DEKA has the full right and power to enter into, and perform its obligations under, this
Agreement, and that, to the best of its knowledge, there are no outstanding agreements, assignments or encumbrances in existence inconsistent with the provisions of this Agreement; and 

d) DEKA is the legal owner of the DEKA Intellectual Property. 

e) DEKA represents, warrants and covenants that it is not, and it is not currently using, and will not in the future use, to perform the
services hereunder, the services of any person or entity, excluded or debarred pursuant to the Generic Drug Enforcement Act of 1992, 21 U.S.C. §335a, as amended, or any similar state law or regulation, excluded by the Office of Inspector
General pursuant to 42 U.S.C. § 1320a-7, et seq., or any state agency from participation in any Federal or state health care program or otherwise disqualified or restricted by the U.S. Food and Drug
Administration pursuant to 21 C.F.R. 312.70 or any other regulatory authority (a “Debarred Person”). DEKA further represents, warrants and covenants that, during the term of this Agreement, DEKA will not hire or employ to provide Services
under this Agreement any person or entity listed on the General Services Administration’s List of Parties Excluded from Federal Programs or on the U.S. Department of Health and Human Services Office of Inspector General’s List of Excluded
Individuals/Entities (each an “Excluded Person”). DEKA shall immediately notify PROKIDNEY in writing if it becomes aware that any person or entity (including DEKA) who is performing services hereunder is or becomes a Debarred Person or
Excluded Person, or to its knowledge, if any action, suit, claim, investigation, or other legal or administrative proceeding is pending or threatened, that would make any person or entity (including DEKA) performing services hereunder a Debarred
Person or Excluded Person, and DEKA shall ensure that such person or entity does not perform services under this Agreement. 
 14.8
PROKIDNEY Representations and Warranties. PROKIDNEY represents and warrants that: 
 a) PROKIDNEY is duly organized, validly existing,
and in good standing under the laws of the Cayman Islands; 

  
 17 

 b) PROKIDNEY has the full right and power to enter into, and perform its obligations under,
this Agreement, and that, to the best of its knowledge, there are no outstanding agreements, assignments or encumbrances in existence inconsistent with the provisions of this Agreement. 

14.9 Limitation of Liability Regarding Representations and Warranties. A Party shall have no liability for any breach of any
representation or warranty herein, including but not limited to any representations and warranties set forth in Sections 14.6 and 14.7, that exceeds one million U.S. dollars ($USD 1,000,000) in the aggregate. 

14.10 Force Majeure. No Party shall be liable for any failure to perform as required by this Agreement to the extent such failure to
perform is caused by any reason beyond the Party’s control, or by reason of any of the following: labor disturbances or disputes, accidents, civil disorders, acts of aggression, acts of God, disease, or similar occurrences. This section shall
not apply to any obligation to make any payment to the other Party. 
 14.11 Compliance with Anti-Corruption Laws. In connection with
this Agreement, the Parties have complied and will comply with all applicable local, national, and international laws, regulations, and industry codes dealing with government procurement, conflicts of interest, corruption or bribery, including
without limitation, if applicable, the U.S. Foreign Corrupt Practices Act of 1977, as amended, and any laws enacted to implement the Organization of Economic Cooperation and Development Convention on Combating Bribery of Foreign Officials in
International Business Transactions. 
 14.12 Assignment. Neither this Agreement nor any rights hereunder may be assigned or
otherwise transferred by a Party without the prior written consent of the other Party, which consent shall not be unreasonably conditioned, withheld, or delayed, except that PROKIDNEY may assign this Agreement and its rights hereunder to a purchaser
of all or substantially all of the assets of PROKIDNEY regardless of the form of the transaction. Subject to the foregoing, this Agreement will be binding upon and inure to the benefit of the Parties and their respective successors and permitted
assigns. 
 14.13 Severability. If any part of this Agreement is held (by final judicial decree) void, invalid or unenforceable, such
ruling shall not affect the validity or enforceability of the remainder of this Agreement, but such part shall be deemed modified to the extent necessary, in the opinion of the judicial authority, to render such term or condition enforceable, and
the rights and obligations of the Parties shall be construed and enforced accordingly, preserving to the fullest permissible extent the intent and agreements of the Parties as set forth in this Agreement. 

14.14 Entire Agreement. This Agreement contains the entire agreement between the Parties relating to the subject matter hereof. No
amendments or modifications to this Agreement shall be effective unless made in writing and signed by an authorized representative of each Party. Further, the Parties agree that the Recitals and the Attachments attached hereto are specifically
incorporated into the Agreement by reference herein. 

  
 18 

 14.15 Governing Law. This Agreement shall be governed by and construed in accordance
with the laws of the State of Delaware, without giving effect to any choice of law provision or rule that would cause the application of the laws of any other jurisdiction. 

14.16 No Public Announcements. No Party, except as required by law, shall originate any publicity, news release or public announcement,
written or oral, whether to the public or press, stockholders or otherwise, relating to this Agreement, including without limitation its existence, the subject matter to which it relates, or any of its terms, to any amendment hereto or performance
hereunder, without the express written permission of the other Party, which permission will not be unreasonably withheld. The Parties expressly agree that PROKIDNEY may disclose the existence of this Agreement, the subject matter to which it
relates, its terms, amendments or either Party’s performance hereunder, in each case to the extent such disclosure is required by the Securities Exchange Act of 1934 or any other law (“Required Disclosure”), which may include, without
limitation, PROKIDNEY’s filing of this Agreement, or some portion thereof, with the Securities and Exchange Commission pursuant to a Current Report on Form 8-K or other Exchange Act report. 

14.17 Compliance with Export Laws. This Agreement is subject to any law, regulation, order or other restriction on the export or re-export of technology licensed under this Agreement as may be imposed from time to time by the governments of the United States, or any other country, or any agency thereof. No Party shall knowingly export or re-export or cause to be exported or re- exported, directly or indirectly, any technology licensed under this Agreement from any other Party to any country for which the
United States or any other government, or any agency thereof, requires an export license or other government approval at the time of such export without first obtaining any required license or approval. 

14.18 Amendments; Waivers. No provision of this Agreement may be waived except by an instrument in writing executed by the Party
against whom the waiver is to be effective. No provision of this Agreement may be amended or otherwise modified except by an instrument in writing executed by or on behalf of the Parties. 

14.19 Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original and
all of which together shall be deemed to be one and the same instrument. 
 14.20 Headings. The headings contained in this Agreement
are for convenience only and shall not affect the meaning or interpretation of this Agreement. 
 ***Signature Page Follows*** 

  
 19 

 IN WITNESS WHEREOF, the Parties hereto have executed this Agreement by their duly authorized
officers or representatives. 
 Date: 
  

			
	DEKA PRODUCTS LIMITED PARTNERSHIP
	By DEKA Research & Development Corp., its sole general partner
		
	By:	 	/s/ Dean Kamen
	Dean Kamen, President

 Date: 
  

			
	DEKA RESEARCH & DEVELOPMENT CORP.
		
	By:	 	/s/ Dean Kamen
	Dean Kamen, President

 Date: January 16, 2022 
  

			
	PROKIDNEY
		
	By:	 	/s/ Pablo Legorreta
		 	 Pablo Legorreta

  
 Signature Page to DEKA
PROKIDNEY RDEL AgreementEX-10.15

 Exhibit 10.15 

MASTER SERVICES AGREEMENT 

This Master Services Agreement (“Agreement”) is made effective as of April 20, 2020 (“Effective Date”) by and between
inRegen, a Cayman Islands company, which has a place of business at 10 Market St., #688 Camana Bay, Grand Cayman KY1-9006 Cayman Islands (“Customer”) and IQVIA RDS Inc. a North Carolina corporation
having its principal place of business at 4820 Emperor Boulevard, Durham, NC 27703 USA, IQVIA Ltd. a company organized under the laws of England and Wales having its principal place of business at 3 Forbury Place, 23 Forbury Road, Reading, United
Kingdom, RG1 3JH, and IQVIA RDS East Asia Ltd. a company organized under the laws of Singapore having its principal place of business at 79 Anson Road, #19-01, Singapore 079906 (collectively
“IQVIA”). When signed by the parties, this Agreement will set forth the terms and conditions under which IQVIA agrees to provide certain services to Customer as set forth herein. 

Recitals: 
 A. Customer is
in the business of developing, manufacturing and/or distributing pharmaceutical products and/or biotechnology products. IQVIA is in the business of providing clinical trial services, research, and other services for the pharmaceutical, medical
device and biotechnology industries. 
 B. Customer and IQVIA desire to enter into this Agreement to provide the terms and conditions upon
which Customer or its affiliates may engage IQVIA or its affiliates from time-to-time to provide services for individual studies or projects by executing individual Work
Orders (as defined below) specifying the details of the services. 
 Agreement: 

 

	1.	 Agreement and Work Orders. 

 

	1.1	 Scope of Agreement. As a master form of contract, this Agreement allows the parties to contract for
multiple projects through the issuance of multiple Work Orders (as discussed in Section 1.3 below), without having to re-negotiate the basic terms and conditions contained herein. 

 

	1.2	 Nature of Services. The services covered by this Agreement may include strategic planning, expert
consultation, clinical trial services, statistical programming and analysis, data processing, data management, regulatory, project management, pharmacovigilance, central laboratory services, clinical pharmacology services, electrocardiogram (ECG)
services, the IQVIA Technology services (as defined in Section 5.3), and other services requested by Customer, and agreed to by IQVIA as set forth in the relevant Work Order (collectively, the “Services”). IQVIA and Customer, where
appropriate or required by law, shall cooperate in the completion of a Transfer of Obligations Form in conjunction with the relevant Work Order. Any responsibilities not specifically transferred in the Transfer of Obligations Form shall remain the
regulatory responsibility of Customer. The Transfer of Obligations Form will be filed with the Food and Drug Administration (“FDA”) by Customer where appropriate, or as required by law or regulation. 

  
 1 

	1.3	 Work Orders. The specific details of the Services for each project under this Agreement (each a
“Project”) shall be set forth in a work order signed by the parties (a “Work Order”). A form Work Order is attached hereto as Exhibit A. Each Work Order will include, as appropriate, the scope of work, time line, and budget and
payment schedule. Each Work Order shall be subject to all of the terms and conditions of this Agreement, in addition to the specific details set forth in the Work Order. To the extent any terms or provisions of a Work Order conflict with the terms
and provisions of this Agreement, the terms and provisions of this Agreement shall control, except to the extent that the applicable Work Order expressly and specifically states an intent to supersede this Agreement on a specific matter. All
exhibits hereto shall be deemed to be incorporated herein by reference. 

  

	1.4	 Change Orders. Any change in the details of a Work Order or the assumptions upon which the Work Order is
based, that requires changes in the budget and/or time lines, shall require a written amendment to the Work Order (a “Change Order”) executed by both parties. IQVIA reserves the right to postpone effecting material changes in the
Project’s scope until such time as the parties agree to and execute the corresponding Change Order. For any Change Order that affects the scope of the regulatory obligations that have been transferred to IQVIA, IQVIA and Customer shall execute
a corresponding amendment to the Transfer of Obligations Form. Customer shall file such amendment with the FDA as required by law or regulation. 

  

	1.5	 Relationship with Affiliates. IQVIA may use the services of its affiliates as subcontractors to fulfill
IQVIA’ s obligations under this Agreement or any Work Order, provided that (a) the affiliate shall be bound in writing by confidentiality and intellectual property provisions at least as restrictive as those contained herein and
(b) the IQVIA entity that is the party to the Work Order shall remain responsible for all such Services performed by its affiliates. Any affiliate of IQVIA or Customer may enter into a Work Order under this Agreement. The terms, conditions and
rights in this Agreement shall be incorporated into the Work Order. The term “affiliate” shall mean all entities controlling, controlled by or under common control with IQVIA or Customer, as the case may be. 

 

	2.	 Payment of Fees and Expenses. 

 

	2.1	 Project Budget. Customer will pay IQVIA the fees, expenses and pass-through costs in accordance with the
budget and payment schedule contained in each Work Order. Depending on the estimated cash flow of the Project and the payment terms, Customer agrees that a prepayment may be needed for IQVIA to maintain cash neutrality over the term of the Project.
For Projects extending over more than one calendar year, the budget may include an annual cost adjustment. 

 The parties
hereby authorize the IQVIA entity that is party to each Work Order to invoice, collect, and receive, in the applicable affiliate’s name and on behalf of such affiliate, for all Services rendered by such affiliate pursuant to this Agreement and
all other amounts payable to such affiliate under each Work Order. Unless the applicable affiliate and IQVIA otherwise agree to a different form and timing of remittance, IQVIA shall remit to the applicable affiliate the portion of the payments
collected or received from Customer on behalf of the affiliate for its provision of Services pursuant to this Agreement and undertaking of the related functions, activities and risks associated with the performance of Services. 

  
 2 

	2.2	 Invoices. IQVIA will invoice Customer in accordance with the budget and payment schedule in each Work
Order for IQVIA’s fees, and monthly for its expenses and pass-through costs incurred in performing the Services. All invoice payments shall be made to IQVIA within thirty (30) days of the invoice date if an invoice is delivered
electronically, or from the date of receipt if Customer requests a paper invoice, except for prepayment and investigator invoices as required in a Work Order, which are due and payable upon receipt. Expenses and pass-through costs will be supported
by a detailed summary sheet. If any portion of an invoice is disputed, then Customer shall pay the undisputed amounts as set forth above and the parties shall use good faith efforts to reconcile the disputed amount as soon as practicable. IQVIA
reserves the right to impose, and Customer agrees to pay if imposed by IQVIA, interest from thirty (30) days after the due date of the invoice in an amount equal to one percent (1%) per month (or the maximum lesser amount permitted by law) of
all undisputed amounts owing hereunder. If Customer requires a purchase order (“PO”) related to an IQVIA invoice, then Customer will provide the PO prior to invoicing by IQVIA. If no PO is provided, IQVIA will invoice Customer without the
PO. If resubmission of an invoice is required based on Customer’s PO requirement or based upon Customer request, IQVIA’s re-submission of that invoice will not change the due date for payment based
on the original invoice. Any provisions contained within a PO that modify, conflict with or contradict any term or provision of this Agreement shall be deemed to be null and void. 

 

	2.3	 Taxes. Customer shall pay all sales and use taxes, including all applicable goods and services tax,
value added tax, local taxes, applicable duties, electronic delivery taxes, excise taxes, levies and import fees (collectively, “Taxes”) that are imposed by legislation in connection with the provision of Services and that are not
recoverable by IQVIA. All fees set forth in a Work Order are exclusive of Taxes. Where Taxes are paid by IQVIA, IQVIA will provide an invoice showing the Taxes included. Where any Taxes are paid directly to a tax authority or government by Customer,
Customer shall not deduct this amount from any amount due to IQVIA. The requirements of this provision shall not apply to any employment-related taxes, duties, income taxes or withholding and shall only apply to Taxes applicable to the Services.

  

	2.4	 Foreign Currency Exchange. The currency to be used for invoicing and payment shall be the currency
stated in the budget or table attached to the applicable Work Order (the “Contract Currency”). 

  

	 	(a)	 Pass-Through Costs. If IQVIA incurs pass-through costs in a currency other than the Contract Currency,
then Customer shall reimburse IQVIA for IQVIA’s actual costs in the Contract Currency based on the Oanda foreign currency exchange rate (Oanda.com) for the applicable currencies on the last business day of the month immediately preceding
the month in which such pass-through costs are paid by IQVIA. 

  
 3 

	 	(b)	 IQVIA’ s Fees. If any Work Order involves the performance of Services by IQVIA or its affiliates in
any country that uses a currency other than the Contract Currency, the Budget for those Services will be based on the local rates in the currency used by IQVIA for pricing in that country (the
“Non-Contract Currency”), but converted to and reflected in the Contract Currency based on the Oanda foreign currency exchange rate (Oanda.com) for the applicable currencies on the last
business day of the month immediately preceding the month in which such fees are invoiced to Customer by IQVIA. If the portion of the fees based on Non-Contract Currencies exceeds the equivalent of US
$3,000,000 (based on the assumptions in the Budget) in any Work Order, inclusive of executed Change Orders, IQVIA will perform an annual reconciliation (at the anniversary of the effective date of the applicable Work Order each year during the term
— the “Contract Anniversary”) of the fees billed in the 12 months prior to the Contract Anniversary compared to the fees that would have been billed based on the application of the Oanda quarterly weighted average Contract Currency
exchange rates to Non-Contract Currency fees. The reconciliation will be performed on the final invoice if the term of the applicable Work Order is less than 12 months. If the reconciliation establishes a
difference of more than 3%, plus or minus, the amount exceeding 3% will be charged or credited to Customer. By way of example only, if the amount of fees billed in Non-Contract Currencies is $1,000,000 in the
12 months prior to the annual reconciliation, and the annual reconciliation determines that the amount that would have been billed during this same time period utilizing the quarterly foreign currency exchange rates equals $950,000, then the
difference equals $50,000, or 5%. Under this example, IQVIA would credit to Customer the amount of $20,000 ($50,000—(3% x $1,000,000)). 

  

	2.5	 Information Requests. If Customer has failed to make any undisputed payments hereunder, and does not
cure such failure within five (5) business days of its receipt of written notice thereof, IQVIA may request that Customer share financial details (such as audited financials, if available) that reasonably demonstrate Customer’s continuing
ability to meet its payment obligations under this Agreement and associated Work Orders (each, an “Information Request”). If Customer declines to provide such financial data within thirty (30) days, then IQVIA may, at its discretion,
notify Customer and deliver an invoice to the Customer, which the Customer agrees to pay upon request, for an additional deposit for a value of up to two (2) months estimated fees and expenses under the applicable Work Order following the date
of notification, with this deposit to be held until the end of the Project and then reconciled against final invoices for the Project. Additionally, Customer shall promptly notify IQVIA upon becoming insolvent or commencing bankruptcy proceedings.
Any information shared with IQVIA pursuant to an Information Request will be subject to IQVIA’s obligations of confidentiality set forth in Section 4.1. 

  
 4 

	3.	 Term and Termination. 

 

	3.1	 Term. This Agreement shall commence on the Effective Date and shall continue for a period of five
(5) years, or until terminated by either party in accordance with this Section 3. The Agreement will automatically renew each year thereafter for a period of one year, unless either party notifies the other party in writing at least ninety
(90) days prior to the renewal date that the notifying party does not want to renew the Agreement. If this Agreement expires but a Work Order hereunder has not been completed or terminated, the terms of this Agreement will continue to apply to
such Work Order as if the Agreement had not expired until such Work Order is completed or terminated. Termination of this Agreement shall terminate all Work Orders. Termination of Work Order shall not result in termination of this Agreement.

  

	3.2	 Termination without Cause. Customer may terminate this Agreement or any Work Order without cause at any
time during the term of the Agreement on sixty (60) days’ prior written notice to IQVIA. 

  

	3.3	 Termination for Cause. Either party may terminate this Agreement or any Work Order (and to the extent
IQVIA is providing Local or Legal Representation Services, it may terminate the provision of such Services) for material breach upon thirty (30) days’ written notice specifying the nature of the breach, if such breach has not been
substantially cured within the thirty (30) day period, provided, however, in the event Customer fails to timely pay any undisputed amounts, IQVIA may at its discretion upon providing five (5) business days prior written notice thereof,
cease extension of credit privileges to Customer; suspend Services (including data transmission) except to the extent that any suspension would reasonably be expected to cause harm to any subject in a clinical trial; and/or withhold payment of
refunds to Customer until such undisputed amounts are paid. 

  

	3.4	 Standards. If IQVIA reasonably determines that its continued performance of the Services contemplated by
one or more Work Orders would constitute a potential or actual violation of regulatory, scientific or ethical standards of integrity, then IQVIA may, in the case of any actual violation, suspend Services under the applicable Work Order(s) (and to
the extent IQVIA is providing Local or Legal Representation Services, it may suspend the provision of such Services) by giving written notice stating the effective date (which may be less than thirty (30) days from the notice date) of such
suspension. The parties shall then cooperate to negotiate a Change Order for the applicable Work Order to correct such potential or actual violation, upon which IQVIA shall resume the Services. If the parties fail to execute a Change Order within
forty-five (45) days following the suspension of Services, either party may terminate the Work Order. 

  

	3.5	 Bankruptcy. Either party may terminate this Agreement or any Work Orders immediately upon provision of
written notice if the other party becomes insolvent or files for bankruptcy. 

  

	3.6	 Identification of Work Order. Any written termination notice shall identify the specific Work Order or
Work Orders that are being terminated. 

  
 5 

	3.7	 Payment. Customer shall pay IQVIA for all Services performed and reimburse IQVIA for all costs and
expenses incurred in accordance with this Agreement and any applicable Work Order, even if the parties’ original payment schedule spreads out payments for certain services or defers payments for certain services until the end of the Project,
with payments to include all non-cancelable and non-avoidable costs incurred prior to termination but paid after the termination date. If payments are unit or milestone
based, and the Agreement or a Work Order is terminated after costs have been incurred toward achieving portions of one or more incomplete units or milestones, Customer will pay IQVIA on a pro-rated basis for
actual work performed toward those incomplete units or milestones up to the date of termination, in addition to paying for completed units or milestones. 

  

	3.8	 Closeout. Upon termination of a Work Order, the parties shall promptly meet to prepare a close-out schedule, and IQVIA shall cease performing all work not necessary for the orderly close-out of the Services or required by laws or regulations. Customer shall pay
for all actual costs, including time spent by IQVIA personnel (at the agreed upon rates), incurred to complete activities reasonably necessary for the termination and close-out of affected Projects, including
the fulfillment of any regulatory requirements. In addition, if the termination is by Customer without cause, or by IQVIA for cause, Customer shall also pay IQVIA for any IQVIA personnel exclusively assigned to the affected Projects at the rates set
forth in the Work Order (provided that such personnel’s time is not already being billed for close-out Services) from the date of termination until such personnel have been assigned to another project, or
until forty-five (45) days from the date of termination, whichever comes first. IQVIA shall make all reasonable efforts to promptly re-assign such personnel. 

 

	4.	 Confidentiality. 

 

	4.1	 Confidential Information. Customer and its affiliates possess certain confidential and proprietary data
and information, including without limitation Customer Technology (as defined in Section 5.1 below) and Customer Property (as defined in Section 5.2 below) (“Customer Confidential Information”), and IQVIA and its affiliates
possess certain confidential and proprietary information pertaining to its operations, methods and pricing, including without limitation IQVIA Property (as defined in Section 5.2 below)(“IQVIA Confidential Information”) (Customer
Confidential Information and IQVIA Confidential Information, including the terms of this Agreement and any Work Order, are each referred to herein as “Confidential Information”). “Confidential Information” does not include
information that is (a) already in the receiving party’s possession at the time of disclosure, as evidenced by the receiving party’s prior written records; (b) part of or becomes part of the public domain through no fault of the
receiving party; (c) received from a third party authorized to provide it; or (d) independently developed by the receiving party, as evidenced by the receiving party’s contemporaneous written records. 

 

	4.2	 Obligations. The Confidential Information shall be used by the receiving party, its affiliates and their
employees only for purposes of performing the receiving party’s obligations hereunder. Each party shall keep confidential all Confidential Information received from the other party or its affiliates, and will not disclose or publish
Confidential Information to third parties without the other party’s prior written consent, provided, however, that IQVIA may disclose limited Confidential Information to third parties performing on behalf of IQVIA or Customer in connection with
this Agreement who have a need to know such Confidential Information, provided that such third party is not a 

  
 6 

	 	competitor of Customer and is bound by confidentiality obligations substantially similar to those set forth herein. Upon the disclosing party’s request or upon completion of the Services, the receiving party shall
promptly cease all use of the disclosing party’s Confidential Information and return it to the disclosing party or, at the disclosing party’s option, certify to the destruction of all Confidential Information; provided, however, that the
receiving party may retain one copy of the disclosing party’s Confidential Information for archival purposes only and Customer may retain IQVIA Confidential Information that is incorporated into any work product and deliverables. These
obligations of confidentiality and nondisclosure shall remain in effect for a period of five (5) years after the completion or termination of this Agreement or the applicable Work Order, whichever is later. 

 

	4.3	 Permitted Disclosures. The receiving party may disclose the disclosing party’s Confidential
Information to the extent required pursuant to any judicial or administrative process or order; provided that the receiving party shall, as soon as practicable and where not prohibited, prior to any such disclosure, give the disclosing party
sufficient notice and reasonable assistance to contest such requirement or order should it wish to do so. The receiving party agrees to reasonably cooperate with the disclosing party, at disclosing party’s expense, in seeking any protective
order or other remedy. 

  

	4.4	 Publicity. Neither party will use the other party’s name in connection with any publication or
promotion without the other party’s prior express written consent. 

  

	4.5	 Equitable Relief. The parties recognize that any threatened breach or breach of this
Section 4 may cause irreparable harm that may be inadequately compensable in damages and that, in addition to other remedies that may be available at law or equity, a party is entitled to seek injunctive relief for such threatened or
actual breach, and the entry of such injunctive relief, shall not preclude a party from seeking any damages or other relief to which it may be entitled under law. 

 

	5.	 Ownership and Inventions. 

 

	5.1	 Customer Property. Excluding IQVIA Property (as defined below), all data and information provided by
IQVIA to Customer as deliverables under this Agreement, and any inventions that are conceived of as the direct result of Services performed by IQVIA under this Agreement, and all intellectual property rights thereto, shall be the sole property of
Customer (“Customer Property”). IQVIA hereby assigns title and interest in all Customer Property to Customer. At Customer’s request and expense, IQVIA shall, and shall cause its affiliates and employees to, execute all documents and
take all actions that Customer reasonably deems necessary to perfect Customer’s ownership of the Customer Property. 

  

	5.2	 IQVIA Property. IQVIA Property is defined as data, data models, databases, inventions, processes, know-how, copyrights, trade secrets, analytical methods, procedures and techniques, manuals, personnel data, pricing, financial information, technical expertise, software, and other intellectual property rights that
are owned by IQVIA or its affiliates prior to the Effective Date. IQVIA Property shall include property that is independently developed by or for IQVIA and its affiliates without incorporation of Customer’s Confidential Information or
Intellectual Property; and any improvements, modifications and enhancements made to the foregoing during the term of this Agreement that do not incorporate any Customer Confidential Information or Intellectual Property. IQVIA and its affiliates own
all right title and interest in and to the IQVIA Property. 

  
 7 

	5.3	 IQVIA Technology. IQVIA Property shall also include its proprietary systems, platforms and applications
(collectively, the “IQVIA Technology”). To the extent that IQVIA provides Services using the IQVIA Technology, Customer grants to IQVIA all rights necessary to use and manage the data entered into the IQVIA Technology solely for the
benefit of Customer and in accordance with this Agreement and applicable laws. If permitted in the applicable Work Order, pursuant to the terms and conditions of this Agreement and that Work Order, Customer shall have the non-exclusive right, during the term specified in that Work Order, to use the IQVIA Technology. Upon expiration or termination of the applicable Work Order, Customer shall promptly cease use of the IQVIA Technology.
Customer shall have no right to use the IQVIA Technology for any purpose other than specifically allowed under this Agreement. IQVIA makes no representations or warranties as to the accuracy of the data entered into the IQVIA Technology provided to
IQVIA or entered by Customer or third parties. IQVIA does not warrant that use of the IQVIA Technology will be uninterrupted or error free, nor does IQVIA make any warranty as to the results to be obtained from the use of the IQVIA Technology.

  

	5.4	 Except as otherwise stated in this Agreement or any Work Order, THE IQVIA TECHNOLOGY, THE SERVICES AND THE
DELIVERABLES DELIVERED HEREUNDER ARE PROVIDED AND DISTRIBUTED ON AN “AS IS” BASIS WITHOUT WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO WARRANTIES OF TITLE,
NON-INFRINGEMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. 

  

	6.	 Records and Materials. 

 

	6.1	 Maintenance of Records. IQVIA shall maintain and retain records relating to the Services and Projects as
provided in each Work Order and per IQVIA SOPs. IQVIA shall ensure that records are protected from destruction or damage and are maintained within IQVIA’s control during the Term of each Work Order unless agreed upon otherwise in a Post-Study
Archiving Agreement. 

  

	6.2	 Return of Customer Materials. At the completion of the Services under a Work Order or upon termination
of this Agreement, IQVIA will deliver to Customer all materials, information and all other data owned by Customer, regardless of the method of storage or retrieval, in such form as is then currently in the possession of IQVIA or as specified in a
Work Order. IQVIA, however, reserves the right to retain, at its own cost and subject to the confidentiality provisions herein, one (1) copy of information as necessary to satisfy regulatory requirements or to resolve disputes regarding the
Services. 

  
 8 

	7.	 Relationship of the Parties. 

 

	7.1	 Independent Contractor. The parties hereto are independent contractors and nothing contained in this
Agreement shall be construed to place them in the relationship of partners, principal and agent, employer/employee or joint venturers. Neither party shall have the power nor right to bind or obligate the other party, and neither party shall hold
itself out as having such authority. 

  

	7.2	 Local Representative. If Customer desires to conduct a trial in one or more countries that require a
local sponsor or representative (the “Local Representative”): (a) to indemnify sites for harm caused by the trial drug, or (b) otherwise assume primary responsibility for: (i) the trial drug, (ii) acting as the importer of
record for any trial drug, devices or other goods, or (iii) the trial in general, including without limitation any procedures required by the protocol, Customer may request that IQVIA serve as Local Representative in such countries and IQVIA
will confirm in writing whether or not it agrees that one or more of its affiliates will act as Local Representative for Customer for a particular project or trial (“Local Representation Services”). 

 

	7.3	 Legal Representative in European Union. If Customer is not based in the European Union (“EU”)
and services will be performed in the EU, Customer may request that IQVIA serve as its legal representative in the EU and IQVIA will confirm in writing whether or not it agrees that one or more of its affiliates will act as Legal Representative for
Customer for a particular project or trial. 

  

	8.	 Regulatory Compliance. 

 

	8.1	 General. IQVIA agrees that its Services will be conducted in compliance with all applicable laws, rules
and regulations, with the standard of care customary in the contract research organization industry. IQVIA’s standard operating procedures will be used in performance of the Services, unless otherwise specifically stated in the applicable Work
Order. Customer further represents that it will reasonably cooperate with IQVIA in taking any actions necessary to comply with the regulatory obligations that have been transferred to IQVIA pursuant to a Transfer of Obligations Form.

  

	8.2	 Debarment. IQVIA represents that it is not and has never been, and neither its employees nor its
affiliates’ employees, nor any subcontractor who will be rendering Services hereunder is currently, (a) debarred or voluntarily excluded or convicted of a crime for which a person can be debarred under 21 U.S.C. § 335(a), as amended,
or any equivalent thereof, in any country in which any portion of the Services are conducted, nor (b) to IQVIA’s knowledge, threatened to be debarred or voluntarily excluded or indicted for a crime or otherwise engaged in conduct for which
a person can be debarred under § 335(a), or subject to any governmental sanction that would prevent the rendering of Services hereunder in any jurisdiction in which the study is to be conducted, nor (c) excluded from participation in any
federally-funded health-care program. In the event that, during the Term, IQVIA becomes so debarred or excluded, IQVIA shall promptly notify Customer and, upon receipt of such notice, Customer shall have the right to terminate this Agreement
immediately. In the event that, during the Term, IQVIA becomes aware of the debarment or exclusion any person or entity providing Services under this Agreement, IQVIA shall notify Customer promptly and cease activities with such person or entity in
connection with the Services. 

  
 9 

	8.3	 Data Protection. Both parties shall at all times abide by all applicable privacy laws and regulations,
and this Agreement, including the Data Processing Agreement attached in Exhibit B. In addition, IQVIA shall at all times abide by its privacy policies and Customer’s instructions when processing personal data under this Agreement. If the
Services will involve the collection or processing of personal data (as defined by applicable data protection legislation) within the European Union (“EU”), then Customer shall serve as the controller of such personal data, as defined by
the General Data Protection Regulation (Regulation (EU) 2016/679 Regulation of the European Parliament and the Council on the Protection of individuals with regard to the processing of personal data and on the free movement of such data)
(“GDPR”), and IQVIA shall act only under the instructions of the Customer in regard to such personal data. If Customer is not based in the EU, Customer must appoint a third party to act as its local data protection representative or
arrange for a co-controller established in the EU for data protection purposes in order to comply with GDPR as IQVIA does not provide this service. 

 

	8.4	 Pharmacovigilance Databases and Systems. In the event a project does not utilize IQVIA’ s
Pharmacovigilance Databases and System, Customer shall be responsible for verifying such systems and databases are of an adequate standard and compliant with applicable law. 

 

	9.	 Audits and Regulatory Inspections. 

 

	9.1	 Customer Audits. During the term of this Agreement, IQVIA will permit Customer’s representatives
(provided that (a) such representatives are not competitors of IQVIA; and (b) prior to any audit Customer shall procure that its non-employee representative enter into a confidentiality agreement
with IQVIA on terms at least as stringent as the confidentiality terms herein) to examine or audit the work performed hereunder and the facilities at which the work is conducted upon reasonable advance notice during regular business hours to
determine that the Project assignment is being conducted in accordance with the agreed task and that the facilities utilized are adequate. Customer agrees that it shall not disclose to any third party any information ascertained by Customer in
connection with any such audit or examination, except to the extent required by law or regulation. 

  

	9.2	 Regulatory Inspections. Each party acknowledges that the other party may respond independently to any
regulatory correspondence or inquiry in which such party or its affiliates is named. Each party, however, shall notify the other party promptly of any FDA or other governmental or regulatory inspection or inquiry concerning any study or Project of
Customer for which IQVIA is providing Services. During any such inspection or inquiry, the parties agree to make reasonable efforts to disclose only the information required to be disclosed. 

  
 10 

	9.3	 Audit and Inspection Costs. Except as provided below, Customer shall reimburse IQVIA for its time and
expenses (including reasonable attorney fees and the costs of responding to findings) associated with any inspection, audit or investigation relating to the Services instigated by Customer or by a governmental authority, unless and to the extent
such inspection, audit or investigation reveals that IQVIA breached this Agreement or any applicable law or regulation; provided, however, during the term of this Agreement Customer shall have the right to audit IQVIA once per year for up to five
(5) days and to conduct reasonable follow up to an audit revealing IQVIA’s breach of this Agreement or any applicable law or regulation, each at IQVIA’ s cost (excluding expenses). 

 

	10.	 Investigators. 

 

	10.1	 Agreements with Investigators. If the applicable Work Order provides that IQVIA will enter into
agreements with investigators or investigative sites (collectively, “Investigators”), IQVIA will use its local Clinical Trial Agreement forms (“CTAs”) unless an industry-standard form is required in the country in question or a
site-specific form is required by a site that has been selected. If no local CTA, site-specific or industry-standard form exists for the country or Investigator as applicable, IQVIA will use its global CTA. Any applicable Local CTAs,
industry-standard forms, site-specific forms, and the Global CTA will be made available for inspection and approval by the Customer. IQVIA and Customer will mutually agree upon CTA negotiation guidelines (the “CTA Guidelines”) in order to
allow IQVIA to negotiate CTAs on the Customer’s behalf. If an Investigator insists upon any material changes to any provisions that are not allowed under or addressed by the CTA Guidelines, IQVIA shall submit the proposed change to Customer,
and Customer shall review, comment on and/or approve such proposed changes within ten (10) working days. IQVIA’s responsibilities with respect to Investigators shall be limited to those responsibilities specifically set forth in this
Agreement or the applicable Work Order. 

  

	10.2	 Payment to Investigators. If IQVIA will be paying Investigators on behalf of Customer: (a) IQVIA
will only pay Investigators from pre-payments received from Customer, (b) IQVIA will not be responsible for delays in a study or Project to the extent that such delays are caused by Customer’s
failure to make such pre-payment, and (c) such payments to Investigators will be separate from payments to IQVIA for its Services. When Customer must publicly report to certain government or regulatory
authorities, information regarding payments or transfers of value made to certain healthcare professionals by or on behalf of Customer to comply with applicable law, IQVIA will prepare and submit financial reports to Customer on a quarterly basis in
a mutually agreeable format. 

  

	11	 Anti-Bribery. Each party undertakes to the other party that: 

 

	 	(a)	 it will not, and will procure that each of its affiliates and each of their respective employees, directors,
officers, subcontractors and agents will not, (i) offer, promise or give an advantage to another person, or (ii) request, agree to receive or accept a financial or other advantage in violation of any anticorruption laws, rules, regulations
and decrees applicable to the respective party (collectively, “Legislation”), including the United States Foreign Corrupt Practices Act, as amended, the United Kingdom Bribery Act 2010 and any implementing legislation under the OECD
Convention Against the Bribery of Foreign Government Officials in International Business Transactions. It is each party’s responsibility to be familiar with, and comply with, the provisions of the applicable Legislation; and

  

	 	(b)	 from time to time, at the reasonable request of the other party, it will confirm in writing that it has
complied with its undertakings under Section 11(a) above and will provide any information reasonably requested by the other party in support of such compliance. 

  
 11 

	12.	 Limitation of Liability. 

 

	12.1	 Consequential Damages. Except for breach of Section 4 (Confidentiality), neither IQVIA, Customer,
their affiliates nor any of their respective directors, officers, employees, subcontractors or agents shall have any liability (including without limitation, contract, negligence and tort liability) for any loss of profits, opportunities or goodwill
or any type of indirect or consequential damages in connection with this Agreement or any Work Order or the Services performed by IQVIA. 

  

	12.2	 Direct Damages Cap. Except for breach of Section 4 (Confidentiality), or in connection with the
obligations under Section 13 (Indemnification) to the extent any claim involves the gross negligence, willful misconduct, or in connection with Third Party Claims for which the third party is not a governmental or regulatory agency, in no event
shall the collective, aggregate liability (including without limitation, contract, negligence and tort liability) of IQVIA or its affiliates, directors, officers, employees, subcontractors or agents under this Agreement exceed the amount of fees
actually received by IQVIA from Customer under the applicable Work Order. 

  

	12.3	 Damages. For purposes of this Section 12, the following, additionally and without limitation, will
be deemed to be direct damages and not consequential damages: (a) court costs and reasonable attorneys’, accounting and other consulting fees and expenses, (b) necessary and appropriate investigatory and third party forensics provider
fees and expenses for the purpose of determining if data was subject to unauthorized access or misappropriation, governmental and regulatory fines, penalties, assessments and/or settlements, (c) the reasonable costs of providing notice to
government or regulatory agencies, media, the public and/or affected individuals whose personal information was misappropriated, provided that any notice is legally required to be provided, (d) the reasonable costs of remediation (including the
cost of twelve (12) months of credit monitoring for individuals whose personal information was misappropriated, call center support and identity theft protection). 

 

	13.	 Indemnification. 

 

	13.1	 Customer Indemnification. Customer shall indemnify, defend and hold harmless IQVIA and its affiliates,
and its and their directors, officers, employees and agents (each, an “IQVIA Indemnified Party”), from and against any and all losses, damages, liabilities, fines, reasonable attorney fees, court costs, and expenses (collectively
“Losses”), resulting or arising from any third-party claims, actions, proceedings, investigations (including subpoenas or other legal process) or litigation (“Third-Party Claims”) arising from this Agreement, any Work Order, or
the Services contemplated herein (including, without limitation, any Losses arising from or in connection with the provision of Local Representation Services and/or any device, product or potential product to which this Agreement or any Work Order
relates), except to the extent such Losses result directly from (a) the gross negligence or intentional misconduct of IQVIA or any IQVIA Indemnified Party or (b) breach of its obligations under this Agreement by IQVIA.

  

	13.2	 IQVIA Indemnification. IQVIA shall indemnify, defend and hold harmless Customer and its affiliates, and
its and their directors, officers and employees (each, a “Customer Indemnified Party”), from and against any and all Losses, resulting or arising from any Third-Party Claims arising from this Agreement, any Work Order, or the Services
contemplated herein, to the extent such Losses result directly from (a) the gross negligence or intentional misconduct of IQVIA or any IQVIA Indemnified Party or (b) breach of its obligations under this Agreement by IQVIA.

  
 12 

	13.3	 Indemnification Procedure. A party seeking indemnification or reimbursement hereunder shall give the
other party prompt notice of any such claim or lawsuit (including a copy thereof) served upon it and shall fully cooperate with the indemnifying party and its legal representatives in the investigation of any matter the subject of indemnification.
The party seeking indemnification shall not unreasonably withhold its approval of the settlement of any claim, liability, or action covered by Section 13.1 or Section 13.2, as applicable, will cooperate with counsel of the indemnifying or
reimbursing party, and reserves the right to engage its own counsel at the indemnified party’s expense. 

  

	14.	 Cooperation; Disclosure of Hazards. Customer shall forward to IQVIA in a timely manner all documents,
materials and information in Customer’s possession or control necessary for IQVIA to conduct the Services. IQVIA shall not be liable to Customer nor be deemed to have breached this Agreement for errors, delays or other consequences arising from
Customer’s failure to timely provide documents, materials or information or to otherwise cooperate with IQVIA in order for IQVIA to timely and properly perform its obligations, and any such failure by Customer shall automatically extend any
timelines affected by a time period reasonably commensurate to take into account such failure, unless Customer agrees in writing to pay any additional costs that would be required to meet the original timeline. Customer shall provide IQVIA with all
information available to Customer regarding known or potential hazards associated with the use of any substances supplied to IQVIA by Customer, and Customer shall comply with all current legislation and regulations concerning the shipment of
substances by the land, sea or air. 

  

	15.	 Force Majeure. In the event either party shall be delayed or hindered in or prevented from the
performance of any act required hereunder by reasons of strike, lockouts, labor troubles (except for strikes, lockouts, labor troubles involving the affected party’s labor force), inability to procure materials or services, failure of power or
restrictive government or judicial orders, or decrees, riots, insurrection, war, Acts of God, inclement weather or other reason or cause beyond that party’s control, then performance of such act (except for the payment of money owed) shall be
excused for the period of such delay. 

  
 13 

	16.	 Notices and Deliveries. Any notice required or permitted to be given hereunder by either party shall be
made in writing and via email if an email address is provided below. Notice shall be deemed given on the date received if delivered personally, by a reputable overnight delivery service, or three (3) days after the date postmarked if sent by
regular, registered or certified mail, return receipt requested, postage prepaid to the following addresses: 

  

			
	 If to IQVIA:
	  	If to Customer:
		
	 IQVIA RDS Inc.

Office of the General Counsel

P.O. Bo 13979
 Research
Triangle Park, NC
 27709-3979

Attention: General Counsel

Email: officeofgeneralcounsel@iqvia.com
	  	 inRegen
 do Twin City Bio, LLC 
3929
WestPoint BLVD 
Suite G
 Winston-Salem, NC 27103 
Attention: CEO

  

	17.	 Insurance. 

  

	17.1	 Customer. During the term of this Agreement and for three (3) years after the expiration or earlier
termination of this Agreement or any Work Order hereunder, whichever is later, Customer shall maintain insurance coverage to cover its obligations under this Agreement and any Work Orders hereunder as follows: (a) clinical trials and/or product
liability by Customer in an amount of at least US $5,000,000 and (b) general liability in amounts of at least US $1,000,000; provided, however, in the event IQVIA is acting as Local Representative hereunder Customer shall maintain clinical
trials and/or product liability by Customer in an amount of at least US $10,000,000 and general liability in amounts of at least US $3,000,000. The Parties acknowledge that clinical trial coverage amounts available and/or required locally may be
less than the limits set forth above, and in such case Customer may meet the full requirements above through a global policy in addition to any local coverage. Customer represents and warrants that it will (a) maintain product
liability/clinical trials insurance that does not contain any conditions or exclusions in the policy that would not normally be included in insurance of this type, and (b) include IQVIA as an additional insured on all applicable clinical trials
and/or product liability policies. 

  

	17.2	 IQVIA. During the term of this Agreement and for four (4) years after the expiration or earlier
termination of this Agreement or any Work Order hereunder, whichever is later, IQVIA shall maintain insurance coverage to cover its obligations under this Agreement and any Work Orders hereunder as follows: (a) professional liability insurance
coverage in an amount of at least US $5,000,000 and (b) general liability in amounts of at least US$1,000,000. IQVIA represents and warrants that it will make Customer an additional insured on IQVIA’s general liability policy.

  
 14 

	17.3	 General Requirements. All insurance coverage under this Section 17 must be issued by an insurance
company that is rated at least A-, VII by A.M. Best. All insurance amounts under this Section 17 may be obtained by full, individual primary policy amount; a primary amount of less than minimum
requirement enhanced by a blanket excess umbrella policy; or a combination of either. Each party shall provide the other party with a certificate of insurance upon request. Each party shall provide the other party with at least thirty (30) days
prior written notice of any cancellation or expiration of the above-required insurance or any material change to such insurance that causes it to no longer comply with the provisions above. In no event shall the obligations set out in this
Section 17 in any way limit or reduce any of either party’s other obligations under this Agreement, including, without limitation, either party’s indemnification obligations set out in Section 13. 

 

	18.	 Binding Agreement and Assignment. This Agreement shall be binding upon and inure to the benefit of
Customer and IQVIA and their respective successors and permitted assigns. Neither party may assign any of its rights or obligations under this Agreement to any party without the express, written consent of the other party, except in event of a
merger or acquisition of substantially all of the assets of the assignor to an assignee with the financial resources to be able to perform the obligations under this Agreement. 

 

	19.	 Choice of Law, Waiver and Enforceability. This Agreement shall be construed, governed, interpreted, and
applied in accordance with the laws of the State of New York, exclusive of its conflicts of law provisions. The failure to enforce any right or provision herein shall not constitute a waiver of that right or provision. Any waiver of a breach of a
provision shall not constitute a waiver of any subsequent breach of that provision. If any provisions herein are found to be unenforceable on the grounds that they are overly broad or in conflict with applicable laws, it is the intent of the parties
that such provisions be replaced, reformed or narrowed so that their original business purpose can be accomplished to the extent permitted by law, and that the remaining provisions shall not in any way be affected or impaired thereby.

  

	20.	 Survival. The rights and obligations of Customer and IQVIA, which by intent or meaning have validity
beyond such termination (including, but not limited to, rights with respect to inventions, confidentiality, discoveries and improvements, indemnification, insurance, data protection and liability limitations) shall survive the termination of this
Agreement or any Work Order. 

  

	21.	 Entire Agreement, Headings and Modification. This Agreement, as amended from time to time, together with
the applicable Work Orders, contains the entire understandings of the parties with respect to the subject matter herein, and supersedes all previous agreements (oral and written), negotiations and discussions. The descriptive headings of the
sections of this Agreement are inserted for convenience only and shall not control or affect the meaning or construction of any provision hereof. Any modifications to the provisions herein must be in writing and signed by the parties.

  

	22.	 Counterparts. This Agreement, a Work Order, Change Order or amendment may be executed by electronic
means (including .PDF) and in any number of counterparts, each of which when executed and delivered, shall constitute an original, but all of which together shall constitute one agreement binding on all parties, notwithstanding that all
parties are not signatories to the same counterpart. 

  
 15 

 IN WITNESS WHEREOF, this Agreement has been executed by the parties hereto through their
duly authorized officers. 
 ACKNOWLEDGED, ACCEPTED AND AGREED TO: 

 

			
	 IQVIA RDS Inc.
	  	inRegen
		
	 By: /s/ Stan Patterson
	  	By: /s/ Timothy A. Bertram
	 Print Name: Stan Patterson
	  	Print Name: Timothy A. Bertram
	 Title: VP, Commercial Operations
	  	Title: CEO
	 Date: 4/30/2020
	  	Date: 29 April 2020

  

	
	 IQVIA Ltd.

	
	 By: /s/ Nicola Kerr

	 Print Name: Nicola Kerr

	 Title: VP, GBO

	 Date: 4/30/2020

	
	 IQVIA RDS East Asia Ltd.

	
	 By: /s/ Roy Toh

	 Print Name: Roy Toh

	 Title: Vice President

	 Date: 5/3/2020

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00347-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00347-of-00352.parquet"}]]